Dihydroartemisinin-piperaquine is the current frontline artemisinin combination therapy (ACT) for Plasmodium falciparum malaria in Cambodia but is now failing in several western provinces. To investigate artesunate plus mefloquine (AS+MQ) as a replacement ACT, we measured the prevalence of multiple pfmdr1 copies--a molecular marker for MQ resistance--in 844 P. falciparum clinical isolates collected in 2008 to 2013. The pfmdr1 copy number is decreasing in Western Cambodia, suggesting that P. falciparum is regaining in vitro susceptibility to MQ.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394809 | PMC |
| http://dx.doi.org/10.1128/AAC.05163-14 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lack of selection of antimalarial drug resistance markers after intermittent preventive treatment of schoolchildren (IPTsc) against malaria in northeastern Tanzania.
Int J Infect Dis
September 2024
Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address:
Article Synopsis
- The study examines the effects of Intermittent Preventive Treatment of schoolchildren (IPTsc) on the genetic markers related to malaria resistance in Plasmodium falciparum in Tanzania, focusing on treatments with dihydroartemisinin-piperaquine (DP) and artesunate-amodiaquine (ASAQ).
- Six specific genetic markers were tracked over 20 months, revealing a significant increase in the prevalence of the Pfmdr1 184F marker but no differences between treatment groups, while other markers maintained consistent prevalence rates.
- The findings suggest that IPTsc does not increase the risk of developing resistance to the used antimalarials, highlighting the need for ongoing monitoring
Antimalarial resistance risk in Mozambique detected by a novel quadruplex droplet digital PCR assay.
Antimicrob Agents Chemother
July 2024
Department of Biology, University of Virginia, Charlottesville, Virginia, USA.
While the malaria parasite continues to cause severe disease globally, Mozambique is disproportionally represented in malaria case totals. Acquisition of copy number variations (CNVs) in the parasite genome contributes to antimalarial drug resistance through overexpression of drug targets. Of interest, piperaquine resistance is associated with plasmepsin 2 and 3 CNVs ( and respectively), while CNVs in the multidrug efflux pump, multidrug resistance-1 (), increase resistance to amodiaquine and lumefantrine.
View Article and Find Full Text PDFDistribution patterns of molecular markers of antimalarial drug resistance in Plasmodium falciparum isolates on the Thai-Myanmar border during the periods of 1993-1998 and 2002-2008.
BMC Genomics
March 2024
Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathumthani, 12120, Thailand.
Background: Polymorphisms of Plasmodium falciparum chloroquine resistance transporter (pfcrt), Plasmodium falciparum multi-drug resistance 1 (pfmdr1) and Plasmodium falciparum kelch 13-propeller (pfk13) genes are accepted as valid molecular markers of quinoline antimalarials and artemisinins. This study investigated the distribution patterns of these genes in P. falciparum isolates from the areas along the Thai-Myanmar border during the two different periods of antimalarial usage in Thailand.
View Article and Find Full Text PDFGenetic characteristics of P. falciparum parasites collected from 2012 to 2016 and anti-malaria resistance along the China-Myanmar border.
PLoS One
November 2023
Coordinator Director Office, Global Malaria Programme, Geneva, Swizerland.
Backgrounds: The therapeutic efficacy studies of DHA-PIP for uncomplicated Plasmodium falciparum patients were implemented from 2012 to 2016 along China (Yunnan province)-Myanmar border, which verified the high efficacy of DHA-PIP. With the samples collected in these studies, the genetic characteristics of P. falciparum parasites based on in vivo parasite clearance time (PCT) was investigated to explore if these parasites had developed resistance to DHA and PIP at molecular level.
View Article and Find Full Text PDFEvolution of genetic markers for drug resistance after the introduction of dihydroartemisinin-piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in Indonesia.
Malar J
August 2023
Eijkman Research Center for Molecular Biology, National Research and Innovation Agency (BRIN), Cibinong, Indonesia.
Article Synopsis
- Dihydroartemisinin-piperaquine has been effective against uncomplicated Plasmodium falciparum malaria in Indonesia, but there's a slight increase in late treatment failures over time despite no artemisinin resistance observed.
- The research analyzed blood samples from malaria patients to investigate genetic markers for drug resistance, finding new SNPs but no SNPs linked to artemisinin resistance, and low levels of piperaquine resistance mutations.
- The findings suggest ongoing efficacy of the treatment, with most late failures attributed to reinfections rather than treatment failure, indicating that while resistance is not a major concern, continued monitoring is essential.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!